Alcoholism, Depression
Conditions
Brief summary
This study will assess whether individuals treated with sertraline (Zoloft) and cognitive behavior therapy will experience improvement with their depression and consume less alcohol than individuals treated with a placebo and cognitive behavior therapy. This is a 12-week, random assignment, placebo-controlled, double-blind study with followup assessments 1 and 3 months after treatment.
Interventions
BEHAVIORALcognitive behavior therapy
Sponsors
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Study design
Allocation
RANDOMIZED
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Meets criteria for major depressive episode. * Meets criteria for alcohol abuse or dependence thirty days prior to entering the study. * Has had no more than one previous inpatient medical detoxification. * Able to maintain sobriety for ten days. * Able to read and understand questionnaires and informed consent. * Lives within 50 miles of the study site, has a stable living situation, and a reliable source of collateral reporting.
Exclusion criteria
* Meets criteria for any other psychoactive substance dependence other than nicotine. * Any psychoactive substance abuse (other than nicotine or marijuana) within 30 days before beginning of study. * Meets criteria for other psychiatric disorders including: panic disorder, obsessive-compulsive disorder, bipolar affective disorder, cyclothymia, schizophrenia, any organic mental disorder, eating disorder, dissociative disorder, or post-traumatic stress disorder. * Has evidence of treatment resistant depression defined as more than one previous treatment episode for depression, which can include hospitalization and/or one course of antidepressant medication. * Patients may not have been prescribed a specific serotonergic medication within the month prior to study and may not have taken any antidepressant or antipsychotic within the two weeks prior to study. * Current use of disulfiram (Antabuse) or anti-seizure medications. * Clinically significant medical problems: cardiovascular, renal, gastrointestinal, or endocrine problems that would limit participation or limit medication ingestion. * Hepatocellular disease. * Females who are pregnant, nursing, or not using a reliable form of birth control. * Current charges pending for violent crime (excluding DUI related offenses). * Previous adverse experience with a serotonin reuptake inhibitor. * Current homicidal or suicidal ideation.
Countries
United States
Outcome results
None listed